Inclusion Criteria:

- NSCLC confirmed by histopathology or cytology;

- Stage IIA or IIIB NSCLC according to Tumor Node Metastasis (TMN) staging of Lung
Staging Standard version 7 2009, and be unresectable;

- Has active mutation of EGFR in exon 19 or 21;

- Has measurable lesion [according to Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1, must have at least one evaluable lesion with the longest dimension >=
10mm; if the evaluable lesion is lymph node, the shortest dimension should be
measured and >=15mm];

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1;

- expectancy life >= 12 weeks;

Exclusion Criteria:

- Had be treated by HER-targeting agents;

- Had systemic anit-NSCLC treatments;

- Had local radiotherapy for NSCLC;

- Has upper gastrointestinal physiological disorders, or malabsorption syndrome, or
intolerance of oral medication, or active peptic ulcer;

- Diagnosed other malignant tumor besides NSCLC within 5 years prior the study
treatment (except having simple surgical resection with 5-year disease free survival,
cured in situ of cervical carcinoma, cured basal cell carcinoma and bladder
epithelial tumor);

- Any evidence to indicate moderate or severe chronic obstructive pulmonary disease
(COPD);

- Known hypersensitivity to platinum, etoposide, EGFR-Tyrosine Kinase Inhibitor (TKI)
agents or relevant components in the formulation;

- Uncontrolled eye inflammation or infection, or any potential circumstances lead to
eye inflammation or infection;